Designtx
NASDAQ: DSGNUnicorn · $1.1BSolana Beach, US · Founded 2017 · 6 known investors
Find your way into Designtx
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform. Its pipeline focuses on monogenic repeat expansion disorders such as Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington's disease.
Founders & leadership
Designtx was founded in 2017 by Pratik Shah, Ph.D. and Aseem Z. Ansari, Ph.D..
Board
Investors · 6
Reported raises · per SEC filings
Form D private placements$170.5M disclosed across 2 rounds · 2020–2021
▶$125MraisedFeb 2021 · 26 investors · PharmaceuticalsRule 506(b)
- Pratik Shah, Ph.D.Executive Officer, Director
- Joao Siffert, M.D.Executive Officer, Director
- Rodney Lappe, Ph.D.Director
- Simeon George, M.D.Director
- Stella Xu, Ph.D.Director
- Sean Jeffries, Ph.D.Executive Officer
- John SchmidDirector
- Arsani William, M.D.Director
- Offering amount
- $125M
- Amount sold
- $125M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$45.5MraisedJun 2020 · 6 investors · PharmaceuticalsRule 506(b)
- Pratik Shah, Ph.D.Executive Officer, Director
- Sean Jeffries, Ph.D.Executive Officer
- Rodney Lappe, Ph.D.Director
- Simeon George, M.D.Director
- Aseem Z. Ansari, Ph.D.Director
- Stella Xu, Ph.D.Director
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Designtx do?
- Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform. Its pipeline focuses on monogenic repeat expansion disorders such as Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington's disease.
- Who founded Designtx?
- Designtx was founded by Pratik Shah, Ph.D., Aseem Z. Ansari, Ph.D. in 2017.
- Who are Designtx's investors?
- Designtx's investors include Avoro Capital Advisors, Quan Capital, RA Capital, SR One Capital Management, WestRiver Group, Quan Venture.
- How much funding has Designtx raised?
- Designtx has disclosed $170.5M raised across 2 rounds.
- Where is Designtx headquartered?
- Designtx is headquartered in Solana Beach, US.